Cabinet Approves Sale Of Surplus Land Of 4 Pharma PSUs
New Delhi: Government on Wednesday approved sale of surplus land of four pharmaceutical public sector undertakings to meet their outstanding liabilities, after which steps to close two units will be taken up.
The sale of surplus land of Hindustan Antibiotics Ltd (HAL), Indian Drugs and Pharmaceuticals Ltd (IDPL), Rajasthan Drugs and Pharmaceuticals Ltd (RDPL) and Bengal Chemicals and Pharmaceuticals Ltd (BCPL) was approved by the Cabinet today, an official statement said.
The sale would be to meet the outstanding liabilities of these public sector undertakings (PSUs), it added.
"The sale would be through open competitive bidding to government agencies and the outstanding liabilities will be met from the sale proceeds," the statement added.
Voluntary Retirement Scheme (VRS) / Voluntary Separation Scheme (VSS) will also be implemented in these organisations.
The remaining part of the land will be managed in accordance with the guidelines of the Department of Investment and Public Assets Management (DIPAM) and Department of Public Enterprises (DPE), the statement said.
"After meeting the liabilities, steps will be taken to close IDPL and RDPL. The option of strategic sale will be explored for HAL and BCPL," the statement said.
The Department of Pharmaceuticals, the administrative department for these undertakings, will take time bound follow-up action, it added.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
